Repeated Chatbot Questionnaires to Spot Heart Failure Getting Worse Early
Looks at repeated symptom questionnaires, answered by chatbot, in adults with heart failure.
Plain-language title generated from the registry record
Registry title: Patient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening
Key facts
- Where
- Moscow, RussiaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term heart failure who were in hospital for heart failure in the last 6 months and now have no signs of fluid build-up.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Long-term heart failure (reduced, mildly reduced or preserved ejection fraction), NYHA class II-III, with a heart failure hospital stay in the last 6 months and no signs or symptoms of congestion now.
- Earlier treatment
- Must have had a heart failure hospital stay in the last 6 months. If loop diuretics (water pills) are prescribed, the oral dose must be stable.
- Biomarker or test result
- At the hospital stay, NT-proBNP of 300 pg/mL or more (sinus rhythm) or 600 pg/mL or more (atrial fibrillation). Now: JVP below 8 cm (3.1 in), no orthopnea, no lung rales, no or trace ankle swelling.
Main reasons for not taking part
- Recent heart attack, heart surgery, stroke, valve repair or urgent stenting in the last 3 months
- Planned heart surgery or heart device or procedure during the study
- Previous heart transplant or waiting for one
- Hemodialysis
- Any active cancer
Read by machine on 9 November 2026.
Where in Russia
- I.M. Sechenov First Moscow State Medical University (Sechenov University)Moscow, RussiaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- I.M. Sechenov First Moscow State Medical University
- Trial code
- NCT07552142
- Record updated
- 27 April 2026
- Original description
This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.Read full original descriptionShow less
Patient-Reported Health Status Assessment Using the Kansas City Cardiomyopathy Questionnaire for Early Detection of Heart Failure Worsening
This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.
Inclusion: Established diagnosis of chronic HF with reduced, mildly reduced, or preserved ejection fraction, NYHA II-III; History of heart failure (HF) hospitalization within the last 6 months before enrollment, defined as the presence of dyspnea, elevated NT-proBNP ≥300 pg/mL (sinus rhythm) or ≥600 pg/mL (if AF), and 2 of the following: i. Rales on chest auscultation or signs of congestion on X-ray/CT scan; ii. Peripheral Oedema; iii. Loop diuretics IV at admission; Free of signs and symptoms of congestion, defined as JVP of <8 cm, with no orthopnea, pulmonary rales, and with trace peripheral edema or no edema; Stable doses of oral loop diuretics, if prescribed; Ability to provide informed consent.
Exclusion: Previous cardiac transplantation and candidates for heart transplantation; Significant drug or alcohol abuse during the last year; Acute coronary syndrome, cardiac surgery, pulmonary embolism, cerebrovascular accident, ablation of atrial flutter/fibrillation, valve repair/replacement, implanted cardioverter defibrillator or urgent PCI within the last 3 months; Planned interventions, including major cardiac surgery (coronary artery bypass grafting, valve repair/replacement, ventricular assist device, cardiac transplantation), coronary revascularization, implantation of a cardiac device or ablation of atrial flutter/fibrillation during the study; Complex congenital heart disease; Heart failure due to active myocarditis, pericardial constriction, known hypertrophic cardiomyopathy or cardiac amyloidosis, or uncorrected severe valvular heart disease; Primary pulmonary hypertension, chronic pulmonary embolism, severe pulmonary disease; Cirrhosis, chronic active hepatitis, or other severe hepatic disease; Any active cancer; Hemodialysis; Infective endocarditis.